BRCA2 and breast carcinoma: This aligns with previous literature of BRCA2 variant carriers receiving RT for breast cancer in which no increase in late toxicity was observed, though the comparison is imperfect given anatomical differences and RT dose rarely exceed 50 Gy in breast RT [53, 54].